RSS

Merck Serono and Medicines for Malaria Venture Sign Agreement to Develop Potential Antimalarial Therapy

  • Worldwide agreement for the investigational antimalarial drug candidate, DDD107498, allows Merck Serono to continue focusing on developing therapies for neglected tropical and poverty-related diseases
  • Agreement cements collaboration between Merck Serono and Medicines for Malaria Venture focused on antimalarial drug development

Darmstadt, Germany, April 1, 2015 – Merck Serono, the biopharmaceutical business of Merck, and Medicines for Malaria Venture (MMV) announced today that an agreement has been signed for Merck Serono to obtain the rights to the investigational antimalarial compound DDD107498 from MMV. This agreement underscores the commitment of Merck Serono to provide antimalarials for the most vulnerable populations in need.

“This agreement strengthens our Global Health research program and our ongoing collaboration with Medicines for Malaria Venture,” said Luciano Rossetti, Executive Vice President, Global Head of Research & Development at Merck Serono. “MMV is known worldwide for its major contribution to delivering innovative antimalarial treatments to the most vulnerable populations suffering from this disease, and at Merck Serono we share this goal.”

mosquito-malaria

DDD107498 originated from a collaboration between MMV and the University of Dundee Drug Discovery Unit, led by Prof. Ian Gilbert and Dr. Kevin Read. The objective of the clinical program is to demonstrate whether the investigational compound exerts activity on a number of malaria parasite lifecycle stages, and remains active in the body long enough to offer potential as a single-dose treatment against the most severe strains of malaria..

While development and commercialization of the compound is under Merck Serono’s responsibility, MMV will provide expertise in the field of malaria drug development, including its clinical and delivery expertise, and provide access to its public and private sector networks in malaria-endemic countries.

Merck Serono has a dedicated Global Health R&D group working to address key unmet medical needs related to neglected diseases, such as schistosomiasis and malaria, with a focus on pediatric populations in developing countries. Its approach is based on public-private partnerships and collaborations with leading global health institutions and organizations in both developed and developing countries.

“Working with partners like Merck Serono is critical to the progress of potential antimalarial compounds, like DDD107498, through the malaria drug pipeline,” said Dr. Timothy Wells, Chief Scientific Officer at MMV. “Their Global Health Program is gaining momentum and we need more compounds to tackle malaria, a disease that places a huge burden on the world’s most vulnerable populations. DDD107498 holds great promise and we look forward to working with the Merck Serono team through the development phase.”

According to the World Health Organization, there were an estimated 198 million cases of malaria worldwide in 2013, and an estimated 584,000 deaths, primarily in young children from the developing world. The launch of the not-for-profit research foundation, MMV, in 1999 and a number of collaborations and partnerships, including those with Merck Serono, has contributed to reducing the major gap in malaria R&D investment and subsequent dearth of new medicines.

“It’s hugely encouraging to see the German pharmaceutical industry increasing their engagement in the development of novel antimalarials,” said global malaria expert Prof. Dr. Peter Kremsner, Director of the Institute for Tropical Medicine at the University of Tübingen, Germany. “The Merck Serono and MMV collaboration to develop DDD107498 is a great step. It’s a compound that offers lots of promise so I’m excited to see how it progresses.”

About Medicines for Malaria Venture
MMV is recognized as the leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

Since its foundation in 1999, MMV has developed and brought to registration four new medicines with its partners, two of which are already saving lives. Managing the largest portfolio of antimalarial R&D projects ever assembled, of over 65 projects, MMV has nine new drugs in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. MMV’s success in research and access & product management comes from its extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries.

MMV’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.

http://www.mmv.org

About Merck Serono
Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit http://www.merckserono.com

All Merck news releases are distributed by e-mail at the same time they become available on the Merck website. Please go to http://www.merckgroup.com/newsabo to register online, change your selection or discontinue this service.

Merck is a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around € 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

 
Leave a comment

Posted by on April 10, 2015 in Merck

 

Tags: , , , ,

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

  • In the second and third quarters of 2015, Merck and Pfizer will begin copromoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom)
  • In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck
  • Co-promotion of XALKORI allows the Merck-Pfizer alliance to establish a combined oncology sales organization in key markets for the program

Darmstadt, Germany, and New York, US, April 7, 2015 – Merck and Pfizer today announced the finalization of the co-promotion agreement allowing the companies to jointly co-promote Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib). This agreement showcases the alliance’s commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.

XALKORI is the first ALK inhibitor approved in the United States, Japan and the European Union (EU) and is supported by two positive global randomized trials in the first- and second-line ALK-positive advanced non-small cell lung cancer (NSCLC) treatment settings. To date, globally more than 8,000 patients have been treated with XALKORI, including those who received XALKORI in clinical trials.

Merck_PfizerUnder the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom). In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck. The second wave will begin in 2016 and includes China and Turkey.

In 2015, Merck will receive a reimbursement associated with its promotion of XALKORI, followed by an 80 percent (Pfizer), 20 percent (Merck) profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the United States, Canada, Japan, France, Germany, Italy, Spain and the United Kingdom and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck.

“We are proud and excited to share the legacy of XALKORI, a medicine that changed the treatment paradigm for patients with ALK-positive metastatic NSCLC, with Merck,” said Liz Barrett, President and General Manager, Pfizer Oncology. “Through our copromotion of XALKORI, we will establish a best-in-class global sales organization that will be exceptionally prepared for the potential launches of our future oncology medicines.”

“As we progress our robust program to co-develop and co-commercialize avelumab, the co-promotion agreement is an exciting milestone for the alliance between Merck and Pfizer, allowing us to establish our combined oncology sales organization in key markets for the program,” said Dr. Andrew Schiermeier, General Manager for the Merck-Pfizer Alliance and Head of Global Oncology, adding: “For Merck, this agreement is particularly important as it accelerates the establishment of our United States and Canada oncology sales organization ahead of our potential avelumab launches and positions us for future success in this market.”

This co-promotion relationship is related to the announcement in November 2014 of a global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational anti-PD-L1 monoclonal antibody, to accelerate the development of immuno-oncology medicines for patients with cancer. The immunooncology alliance will also advance Pfizer’s PD-1 antibody. *Avelumab is the proposed International Nonproprietary Name (INN) for the anti‐PD‐L1 monoclonal antibody (MSB0010718C)

About Non-small Cell Lung Cancer
Globally, lung cancer is the most common cause of cancer-related deaths in men and the second most common in women, responsible for almost twice as many deaths as both breast and prostate cancer combined1. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85 to 90 percent of all lung cancers2. Locally advanced and metastatic disease account for approximately 35 to 40 percent3 and 70 percent4 of patients, respectively with NSCLC.

About XALKORI® (crizotinib)
XALKORI is a kinase inhibitor indicated in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The US indication is not limited to any specific line of therapy. In the EU, XALKORI is indicated for the treatment of adults with previously treated ALK-positive advanced NSCLC. XALKORI has received approval in more than 80 countries. For more information and full prescribing information, please see:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002489/WC500134759.pdf.

Merck-Pfizer Alliance
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high priority immuno-oncology clinical development programs, including combination trials, many of which are expected to commence in 2015.

Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and
significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more,
please visit us at http://www.pfizer.com.

Merck
Merck of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Pfizer Disclosure Notice
The information contained in this release is as of April 7, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an agreement between Pfizer and Merck to copromote Pfizer’s XALKORI in certain markets as well as about the companies’ immuno-oncology alliance involving avelumab and Pfizer’s anti-PD-1 antibody and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the success of the co-promotion arrangement and whether the companies will realize the anticipated benefits of the co-promotion arrangement; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data, including the risk that the final results of the Phase I study for avelumab and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further clinical development; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential product candidates or combination therapies; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of any of such product candidates or combination therapies; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at http://www.sec.gov and http://www.pfizer.com.

References
1. American Cancer Society. (2011). Global Facts & Figures Second Edition. Retrieved from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
2. American Cancer Society. (2014). Lung Cancer (Non-Small Cell) [Fact sheet]. Retrieved from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
3. Blumenschein, G. R., Paulus, R., Curran, W. J., Robert, F., Fossella, F., Werner-Wasik, M., Herbst, R. S., Doescher, P. O., Choy, H., & Komaki, R. (2011). Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 17, 2312–2318.
4. Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2013). The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer treatment reviews, 4,558–566.

 
Leave a comment

Posted by on April 9, 2015 in Industry

 

Tags: , , , , ,

Merck Serono India Wins the ‘Healthcare Leadership Awards 2015′

Merck Serono India Wins the 'Healthcare Leadership Awards 2015'Merck Serono India Wins the ‘Healthcare Leadership Awards 2015′ for the ‘Fertility Awareness Month 2014 in the Best Marketing Campaign category’ held on the 14th February, 2015 at Taj Lands End, Mumbai.

This is the 2nd consecutive year that Merck Serono India has been awarded this recognition in the same category for the outstanding Digital Marketing Programmes during our Fertility Awareness Month 2014.

This is testimony to the fact that the Merck Serono India is at the forefront of the Digital and Multi-Channel Marketing in Healthcare and has leadership in these areas and further differentiate ourselves in the industry.

These awards witnessed participation from leading Healthcare Organisations, MNCs, Pharmaceuticals Companies and Media Giants such as Ogilvy & Mather, Law & Kenneth, McCann Health, Impact Communications, Abbott Healthcare, to name a few.

Healthcare Leadership Awards highlights winning work and offers well deserved recognition. These awards recognizes innovative growth strategies and solutions adopted by the best companies in the healthcare industry. The awards are unique Healthcare Awards recognize projects and professionals that lead innovative Healthcare practices and make a difference to patients’ lives in the healthcare science and allied health professions.

 
Leave a comment

Posted by on March 26, 2015 in Industry

 

Tags: , , , , , , , , ,

Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology

Collaboration strengthens Merck Serono’s position as a leader in precision medicine in oncology

Darmstadt, Germany, March 10, 2015 – Merck Serono, the biopharmaceutical business of Merck, and Illumina, Inc., today announced a collaboration to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies.

Merck Serono _Illunmina

Under the terms of the agreement, will work together to develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting. Illumina’s successful regulatory track record was an important consideration in the collaboration, as next-generation sequencing platforms cleared by a regulatory agency could accelerate the development of an assay and facilitate the registration of a companion diagnostic.

“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, Head of Global Business Development at Merck Serono. “This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology.”

The collaboration will include development of the diagnostic, worldwide regulatory approvals, and global commercialization.

“This agreement is another step forward in realizing the promise of precision medicine,” said Richard Klausner, M.D., Illumina’s Chief Medical Officer. “There is a clear need to expand genetically-based clinical trials as a key approach for developing better treatments for cancer. We are very excited to work with Merck Serono on this endeavor.”

This collaboration complements Merck Serono’s existing partnerships in the area of diagnostics, including Life Technologies and Dako, allowing Merck Serono to choose from a wide variety of technologies in implementing a precision medicine strategy.

About Merck Serono
Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit http://www.merckserono.com

All Merck news releases are distributed by e-mail at the same time they become available on the Merck website. Please go to http://www.merckgroup.com/newsabo to register online, change your selection or discontinue this service.

Merck is a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around € 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

 
Leave a comment

Posted by on March 12, 2015 in Industry

 

Merck Serono Fertility Pen Receives GOOD DESIGN Award

Design Award Exemplifies Merck Serono’s Commitment to Developing Innovative Drug Delivery Devices that Benefit the Lives of Patients

gonal_f_pen

The Gonal-f RFF Redi-ject (US brand name) and Gonal-f Pen 1.0 (brand name Europe and Rest of the World) received the GOOD DESIGN Award for Design Excellence. The annual award program recognizes the most innovative and cutting-edge industrial, product and graphic designs produced around the world.

Bharat Tewarie, Head of the Global Business Franchise Medical Devices (GBF MD), hailed the prestigious GOOD DESIGN Award for Design Excellence for the Gonal-f RFF Redi-ject Pen (including Pen 1.0 launched in countries outside of the US) as a remarkable achievement, signaling the critical importance of the collaboration between the GBF MD, Global Business Franchise Fertility (GBF F) and our manufacturing partner Haselmeier. He said, “This represents a union of some of Merck Serono’s greatest talent with an outside partner to develop a therapy and device that truly betters the lives of patients.”

The Gonal-f RFF Redi-ject and Gonal-f Pen 1.0 is a disposable, pre-filled drug delivery system intended for subcutaneous injection of multiple and variable doses of a liquid formulation of follitropin alfa. Gonal-f is prescribed to supplement or replace naturally occurring follicle-stimulating hormone (FSH), an essential hormone to treat infertility, and as the world’s first recombinant human follicle-stimulating hormone (r-hFSH), Gonal-f has been approved in 112 countries worldwide – among which 74 countries have approved the Gonal-f pre-filled pen – including Europe and the US with indications of induction of ovulation and multiple follicular development in women undergoing assisted reproductive technology (ART). Gonal-f is the most widely prescribed gonadotropin in the world.

This award serves as a reminder of the importance of working as One for Patients at Merck Serono to understand the unmet needs of patients and offer them solutions.

This award is also a nod to the innovation and creativity that have become standard in the work GBF MD does. In 2014, Merck Serono demonstrated its commitment to innovation with the launch of its first-in-class adherence monitoring drug delivery device and its pursuit of other e-health devices. Furthermore, this status as a significant contributor to innovation in the medical device space was validated at the company’s first ever Medical Devices Innovation Day where presenters from Apple, Rewalk, Matternet, MyVisionTrack, Massachusetts Institute of Technology (MIT) and others shared the latest medical device news from their companies.

The emphasis of the GOOD DESIGN program is on quality design of the highest form, function and aesthetics, a standard beyond ordinary consumer products and graphics. It forwards the ideals of a design process that embodies product excellence, endurance and strong public identity.

Founded in Chicago in 1950 by the former MoMA curator Edgar Kaufmann, Jr., together with such pioneers in modern design as Charles and Ray Eames, Russel Wright, George Nelson and Eero Saarinen, GOOD DESIGN honors the yearly achievements of the best industrial and graphic designers and world manufacturers for their pursuit of extraordinary design excellence.

All award winning products and graphic designs are published in the GOOD DESIGN Yearbook for 2014-2015 and will be published online at http://www.chi-athenaeum.org

 
Leave a comment

Posted by on March 11, 2015 in Industry

 

International Women’s Day – Merck Celebrates “Healthy Women, Healthy Economies”

“Improving women’s health—which includes ongoing pharmaceutical innovation and support for access and awareness—is a strategic priority for Merck.” Belén Garijo, CEO of Merck.

Did you know?

  • Cardiovascular disease is the number one killer of women worldwide 1
  • Diseases such as thyroid disorders, multiple sclerosis, and lupus affect as much as ten times more women than men 2,3,4
  • More than 72.4 million reproductive-aged women across the world are currently experiencing infertility5

Health-India

March 8th was International Women’s Day, which is celebrated annually to recognize women’s achievements and raise awareness of the struggles of women globally. A key element for women’s advancement is their ability to access quality health care. Furthermore, it is becoming even more critical that women are fully integrated into the economy as populations age, birth rates drop, and workforces shrink. Healthy Women lead to Healthy Economies.

Belén Garijo, CEO of Merck Healthcare, explains, “Merck Serono is a leader in women’s health. I am honored that we are the private sector co-chair of the ‘Healthy Women, Healthy Economies’ initiative, which brings together patients, health care organizations, governments, NGOs, and academia to develop a policy checklist for improving women’s access to health.”

Merck is committed to improving women’s health with leading-edge disease therapies and through awareness, outreach, and meaningful partnerships with stakeholders, not just on International Women’s Day but every day.

1 World Health Organization World Health Organization. (2013, September). Women’s Health Fact Sheet. Retrieved February 26, 2015, from http://www.who.int/mediacentre/factsheets/fs334/en/
2 American Thyroid Association. (n.d.). General Information/Press Room. Retrieved February 26, 2015, from http://www.thyroid.org/media-main/about-hypothyroidism/
3 National Multiple Sclerosis Society. (n.d.). Multiple Sclerosis FAQs. Retrieved February 26, 2015, from http://www.nationalmssociety.org/What-is-MS/MS-FAQ-s
4 American College of Rheumatology. (2013, February). Systemic Lupus Erythematosus (Lupus). Retrieved February 26, 2015, from https://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions
/Systemic_Lupus_Erythematosus_(Lupus)/

5 Boivin, J., Bunting, L., Collins, J., & Nygren, K. (2007). International estimates of infertility prevalence and treatment-seeking: Potential need and demand for infertility medical care. Human Reproduction 22(6), 1506-1512. Retrieved February 26, 2015, from http://humrep.oxfordjournals.org/content/22/6/1506.long

 
Leave a comment

Posted by on March 9, 2015 in Industry

 

Merck Finishes Year of Key Strategic Moves with Record Figures

  • Good operating business and acquisition of AZ boost sales (+5.5%) and EBITDA pre one-time items (+4.1%) to new record levels
  • Organic growth in all four divisions
  • Business in Emerging Markets drives sales
  • Merck lays foundations for future growth
  • Forecast for sales and EBITDA pre one-time items met
  • Merck proposes a 5.3% increase in the dividend to € 1.00 per share

Untitled

Darmstadt, Germany, March 3, 2015 – Merck, a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials, has successfully completed a year of strategically important moves and achieved its objectives.

“We strengthened all three of Merck’s business sectors: Healthcare, Life Science and Performance Materials. With the acquisition of AZ, the offer to acquire Sigma-Aldrich and the alliance with Pfizer in immuno-oncology, we have laid the foundations for future growth,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck, on Tuesday in Darmstadt. “These developments are the result of our long-term transformation and growth strategy. Merck is transforming into a highly specialized, global technology company with the goal to improve the lives of patients and customers.”

Total revenues of the Merck Group rose by 3.7% to € 11.5 billion in 2014 (2013: € 11.1 billion). Sales grew by 5.5% to € 11.3 billion (2013: € 10.7 billion). This was primarily the result of organic growth of 4.0% as well as acquisition-related increases of 3.3%, which were attributable to the acquisition of AZ. At the same time, foreign exchange effects lowered sales by -1.8%.

Click on the following links for the full coverage –
Full Press Release
Online Report
Press Conference
The Year 2014 in Moving Images (Video)

Read more about the Fiscal Year 2014 at Merck

 
Leave a comment

Posted by on March 3, 2015 in Industry

 
 
Follow

Get every new post delivered to your Inbox.

Join 62,214 other followers